These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
213 related articles for article (PubMed ID: 30466771)
1. Secondary Hypogammaglobulinemia: An Increasingly Recognized Complication of Treatment with Immunomodulators and After Solid Organ Transplantation. Kaplan B; Bonagura VR Immunol Allergy Clin North Am; 2019 Feb; 39(1):31-47. PubMed ID: 30466771 [TBL] [Abstract][Full Text] [Related]
2. Hypogammaglobulinemia and infection risk in solid organ transplant recipients. Mawhorter S; Yamani MH Curr Opin Organ Transplant; 2008 Dec; 13(6):581-5. PubMed ID: 19060546 [TBL] [Abstract][Full Text] [Related]
3. Practical guidance for the diagnosis and management of secondary hypogammaglobulinemia: A Work Group Report of the AAAAI Primary Immunodeficiency and Altered Immune Response Committees. Otani IM; Lehman HK; Jongco AM; Tsao LR; Azar AE; Tarrant TK; Engel E; Walter JE; Truong TQ; Khan DA; Ballow M; Cunningham-Rundles C; Lu H; Kwan M; Barmettler S J Allergy Clin Immunol; 2022 May; 149(5):1525-1560. PubMed ID: 35176351 [TBL] [Abstract][Full Text] [Related]
4. Does increasing immunoglobulin levels impact survival in solid organ transplant recipients with hypogammaglobulinemia? Florescu DF; Kalil AC; Qiu F; Grant W; Morris MC; Schmidt CM; Florescu MC; Poole JA Clin Transplant; 2014 Nov; 28(11):1249-55. PubMed ID: 25203509 [TBL] [Abstract][Full Text] [Related]
5. Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections. Casulo C; Maragulia J; Zelenetz AD Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):106-11. PubMed ID: 23276889 [TBL] [Abstract][Full Text] [Related]
6. Immunological risk factors for infection after immunosuppressive and biologic therapies. Carbone J; del Pozo N; Gallego A; Sarmiento E Expert Rev Anti Infect Ther; 2011 Apr; 9(4):405-13. PubMed ID: 21504398 [TBL] [Abstract][Full Text] [Related]
7. Profound symptomatic hypogammaglobulinemia: a rare late complication after rituximab treatment for immune thrombocytopenia. Report of 3 cases and systematic review of the literature. Levy R; Mahévas M; Galicier L; Boutboul D; Moroch J; Loustau V; Guillaud C; Languille L; Fain O; Bierling P; Khellaf M; Michel M; Oksenhendler E; Godeau B Autoimmun Rev; 2014 Oct; 13(10):1055-63. PubMed ID: 25183241 [TBL] [Abstract][Full Text] [Related]
8. Immunoglobulin G replacement for the treatment of infective complications of rituximab-associated hypogammaglobulinemia in autoimmune disease: a case series. Roberts DM; Jones RB; Smith RM; Alberici F; Kumaratne DS; Burns S; Jayne DR J Autoimmun; 2015 Feb; 57():24-9. PubMed ID: 25586449 [TBL] [Abstract][Full Text] [Related]
9. Secondary antibody deficiency: a complication of anti-CD20 therapy for neuroinflammation. Tallantyre EC; Whittam DH; Jolles S; Paling D; Constantinesecu C; Robertson NP; Jacob A J Neurol; 2018 May; 265(5):1115-1122. PubMed ID: 29511864 [TBL] [Abstract][Full Text] [Related]
10. Antibody replacement therapy in primary antibody deficiencies and iatrogenic hypogammaglobulinemia. Hoffman TW; van Kessel DA; van Velzen-Blad H; Grutters JC; Rijkers GT Expert Rev Clin Immunol; 2015; 11(8):921-33. PubMed ID: 26181342 [TBL] [Abstract][Full Text] [Related]
11. The Expanding Field of Secondary Antibody Deficiency: Causes, Diagnosis, and Management. Patel SY; Carbone J; Jolles S Front Immunol; 2019; 10():33. PubMed ID: 30800120 [TBL] [Abstract][Full Text] [Related]
12. Decreased immunoglobulin G levels after living-donor liver transplantation is a risk factor for bacterial infection and sepsis. Yoshizumi T; Shirabe K; Ikegami T; Yamashita N; Mano Y; Yoshiya S; Matono R; Harimoto N; Uchiyama H; Toshima T; Maehara Y Transpl Infect Dis; 2014 Apr; 16(2):225-31. PubMed ID: 24593220 [TBL] [Abstract][Full Text] [Related]
13. A national survey of screening and management of hypogammaglobulinemia in Canadian transplantation centers. Bourassa-Blanchette S; Knoll G; Tay J; Bredeson C; Cameron DW; Cowan J Transpl Infect Dis; 2017 Aug; 19(4):. PubMed ID: 28423227 [TBL] [Abstract][Full Text] [Related]
14. Immunoglobulin replacement for secondary immunodeficiency after B-cell targeted therapies in autoimmune rheumatic disease: Systematic literature review. Wijetilleka S; Mukhtyar C; Jayne D; Ala A; Bright P; Chinoy H; Harper L; Kazmi M; Kiani-Alikhan S; Li C; Misbah S; Oni L; Price-Kuehne F; Salama A; Workman S; Wrench D; Karim MY Autoimmun Rev; 2019 May; 18(5):535-541. PubMed ID: 30844552 [TBL] [Abstract][Full Text] [Related]
16. Secondary hypogammaglobulinemia in patients with multiple sclerosis on anti-CD20 therapy: Pathogenesis, risk of infection, and disease management. Alvarez E; Longbrake EE; Rammohan KW; Stankiewicz J; Hersh CM Mult Scler Relat Disord; 2023 Nov; 79():105009. PubMed ID: 37783194 [TBL] [Abstract][Full Text] [Related]
17. [Persistent hypogammaglobulinemia in an ITP patient following treatment with rituximab]. Toubi E Harefuah; 2012 Nov; 151(11):620-1, 655. PubMed ID: 23367731 [TBL] [Abstract][Full Text] [Related]
18. Rituximab-associated hypogammaglobulinemia: incidence, predictors and outcomes in patients with multi-system autoimmune disease. Roberts DM; Jones RB; Smith RM; Alberici F; Kumaratne DS; Burns S; Jayne DR J Autoimmun; 2015 Feb; 57():60-5. PubMed ID: 25556904 [TBL] [Abstract][Full Text] [Related]
19. Pulmonary Manifestations of Immunodeficiency and Immunosuppressive Diseases Other than Human Immunodeficiency Virus. Pacheco SE; Stark JM Pediatr Clin North Am; 2021 Feb; 68(1):103-130. PubMed ID: 33228927 [TBL] [Abstract][Full Text] [Related]
20. Diagnostic and therapeutic considerations in patients with hypogammaglobulinemia after rituximab therapy. Kado R; Sanders G; McCune WJ Curr Opin Rheumatol; 2017 May; 29(3):228-233. PubMed ID: 28240614 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]